📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
DCAL Clarifies Credit Rating Downgrade to 'A' Despite Improving Leverage and Margins
India Ratings & Research (IND-RA) has downgraded Dishman Carbogen Amcis Limited's (DCAL) long-term credit rating from 'A+' to 'A' and short-term rating from 'A1+' to 'A1' with a negative outlook. In response, the company issued a clarification highlighting that its financial health is actually improving, with net leverage dropping from 3.92x in March 2025 to 3.18x in September 2025. DCAL also noted that EBITDA margins for its core operations (excluding specific new sites) have reached 25.68%, which is higher than pre-EDQM observation levels. The company expects consolidated performance to strengthen as its newly re-approved Bavla site and French facility scale up.
Key Highlights
Long-term credit rating downgraded to 'A' with a Negative outlook from 'A+' Stable.
Net leverage improved significantly to 3.18x in Sept 2025 from 3.92x in March 2025.
Net debt excluding Fx impact reduced from ₹16,164 million to ₹14,238 million in six months.
Core EBITDA margins (excluding France and India sites) rose to 25.68% in 6MFY26 vs 24.35% in FY20.
Consolidated EBITDA margins improved to 19.35% in 6MFY26 from 17.40% in FY25.
💼 Action for Investors
Investors should closely monitor the operational ramp-up at the Bavla and French sites, as their success is key to improving the consolidated credit profile. While the rating downgrade is a negative signal, the improving leverage and core margin trends suggest the company is on a recovery path.
DCAL Subsidiary Receives GMP Compliance Certificate for Netherlands Site
Dishman Carbogen Amcis Limited's wholly-owned subsidiary, CARBOGEN AMCIS B.V., has received a Certificate of GMP Compliance for its manufacturing site in Veenendaal, Netherlands. The certification was issued by the Health and Youth Care Inspectorate (IGJ), the competent authority in the Netherlands, following a successful inspection. This regulatory milestone confirms that the facility adheres to Good Manufacturing Practice standards required for pharmaceutical production. Such approvals are critical for maintaining operational continuity and serving global pharmaceutical clients from European facilities.
Key Highlights
Wholly-owned subsidiary CARBOGEN AMCIS B.V. secured GMP compliance on February 20, 2026.
The certification specifically covers the Veenendaal site located in the Netherlands.
Approval was granted by the Health and Youth Care Inspectorate (IGJ), a key European regulator.
The compliance ensures the facility meets international quality standards for pharmaceutical manufacturing.
💼 Action for Investors
Investors should view this as a positive development that reduces regulatory risk and supports the company's high-margin European operations. Maintain a long-term outlook as the company continues to validate its manufacturing capabilities in regulated markets.
India Ratings Downgrades DCAL to 'IND A' with Negative Outlook on High Leverage
India Ratings & Research has downgraded Dishman Carbogen Amcis Limited's (DCAL) credit rating for NCDs and bank facilities to 'IND A' with a Negative outlook. The downgrade reflects persistently high consolidated net adjusted leverage, which stood at 3.92x in FY25, and EBITDA margins that remain significantly below pre-regulatory issue levels. While the company has resolved major USFDA and EDQM issues, the ramp-up of its India CRAMS business and new French facility has been slower than anticipated. Management is planning an INR 10 billion capital raise via QIP to repay high-cost debt and target a leverage ratio below 2.5x.
Key Highlights
Credit rating for NCDs and bank facilities downgraded to 'IND A' with a Negative outlook.
Consolidated net adjusted leverage improved to 3.92x in FY25 from 6.35x in FY24 but remains above comfort levels.
EBITDA margins for 3QFY26 fell to 15.7% compared to 22.8% in the previous year's quarter.
Robust order book of CHF 114 million for development and CHF 85 million for commercial projects as of Dec 2025.
Management intends to raise INR 10 billion through QIP or preferential shares to deleverage the balance sheet.
💼 Action for Investors
Investors should exercise caution as the downgrade reflects stretched debt metrics; the successful execution of the proposed INR 10 billion fundraise is critical for financial stability. Monitor the ramp-up of the Bavla and French facilities for signs of EBITDA margin recovery toward the 20% mark.
DCAL Q3 FY26 Revenue Grows 5.5% to INR 720 Cr; 9M EBITDA Margins Improve to 19.4%
Dishman Carbogen Amcis (DCAL) reported a 5.5% YoY revenue growth in Q3 FY26, reaching INR 720 crores, despite a shipment delay of INR 20 crores that shifted to January. While the quarter saw a net loss of INR 12.97 crores due to one-time refinancing costs and higher COGS from commercial supplies, the nine-month performance remains strong with a PAT of INR 75.7 crores. EBITDA margins for the nine-month period improved significantly to 19.4% from 15.9% in the previous year, driven by high-margin development revenue. The company is benefiting from lower borrowing costs in Switzerland and successful quality audits at its European facilities.
Key Highlights
Q3 FY26 revenue reached INR 720 crores, up 5.5% YoY, despite INR 20 crores in shipments being delayed to Q4.
9M FY26 EBITDA grew 27.3% YoY to INR 403 crores, with margins expanding from 15.9% to 19.4%.
Finance costs included a one-time INR 11 crore expense for debt refinancing; however, Swiss borrowing costs have dropped to 3-3.5%.
Company successfully passed a mock FDA audit at the Vionnaz site and is progressing on a co-investment expansion project with a Japanese customer.
Employee expenses rose to INR 355 crores in Q3, including provisions for severance packages and social insurance.
💼 Action for Investors
Investors should monitor the realization of delayed revenue in Q4 and the sustained improvement in EBITDA margins. The reduction in Swiss interest rates and successful quality audits provide a positive outlook for debt servicing and regulatory compliance.
DCAL Q3 Revenue Up 5.5% to Rs 7,198 Mn; EBITDA Margins Contract to 15.7%
Dishman Carbogen Amcis (DCAL) reported a modest 5.5% YoY revenue growth in Q3FY26, reaching Rs 7,198 million. However, the quarter saw a significant hit to profitability as EBITDA fell 19.3% YoY to Rs 1,131 million, with margins shrinking from 20.5% to 15.7%. This decline was primarily due to a lower contribution from high-margin late-phase III molecules in the CDMO segment. Despite the weak quarter, the 9-month performance remains positive with EBITDA up 27.3% and margins improving to 19.4% compared to the previous year.
Key Highlights
Q3FY26 revenue increased 5.5% YoY to Rs 7,198 mn, while 9MFY26 revenue rose 4.3% to Rs 20,805 mn.
Quarterly EBITDA margins contracted to 15.7% from 20.5% in Q3FY25 due to unfavorable product mix.
CDMO segment revenue grew 6.7% YoY in Q3, but segment margins dropped from 22.1% to 16.9%.
Marketable Molecules segment revenue fell 2.4% in Q3 with margins dropping to 7.2% due to high cholesterol revenue composition.
Revenue of approximately Rs 200 million was deferred from Q3 to Q4FY26 due to supply chain delays and European holidays.
💼 Action for Investors
Investors should be cautious of the sharp quarterly margin contraction and monitor if the deferred Rs 200 million revenue and high-margin CDMO projects recover in Q4. The long-term 9-month trend shows improvement, but the volatility in project-based CDMO margins remains a key risk.
DCAL Q3 FY26 Revenue Grows 5.5% to ₹7,198 mn; 9M PAT Turns Positive at ₹757 mn
Dishman Carbogen Amcis (DCAL) reported a 5.5% YoY revenue growth in Q3 FY26, reaching ₹7,198 million, led by a 6.7% increase in the CDMO segment. While the company faced a net loss of ₹129.7 million in Q3 due to one-time expenses and margin contraction, the 9-month performance shows a significant turnaround with a PAT of ₹757 million compared to a loss last year. Management highlighted that ₹200 million in revenue was deferred to Q4 due to supply delays in Europe, and the company maintains a strong pipeline of 10 molecules in Late Phase III development.
Key Highlights
Q3 FY26 Revenue rose 5.5% YoY to ₹7,198 mn, while 9M FY26 Revenue reached ₹20,805 mn.
EBITDA margins for Q3 contracted to 15.7% from 20.5% YoY, though 9M margins improved to 19.4%.
One-time costs impacted Q3, including ₹110 mn in finance expenses for new credit facilities and ₹33 mn in severance pay.
The CDMO segment remains the primary driver, contributing 87% of Q3 revenue at ₹6,297.4 mn.
Maintains a robust pipeline with 10 molecules in Late Phase III and 29 total commercialized molecules.
💼 Action for Investors
Investors should focus on the company's ability to maintain the 9-month profitability trend and the successful commercialization of its Late Phase III pipeline. The Q3 margin dip appears driven by temporary one-off costs and revenue deferrals, making Q4 performance critical for validation.
DCAL Reports Q3 FY26 Consolidated Net Loss of ₹12.97 Cr; Operating Margins Contract to 15.71%
Dishman Carbogen Amcis Limited (DCAL) reported a consolidated net loss of ₹12.97 crore for the quarter ended December 31, 2025, a sharp reversal from a profit of ₹65.27 crore in the preceding quarter. While total income from operations grew 5.5% year-on-year to ₹719.80 crore, profitability was weighed down by higher employee benefit expenses and depreciation. The operating margin saw a significant contraction to 15.71% compared to 20.61% in the year-ago period. Despite the quarterly loss, the 9-month performance remains positive with a net profit of ₹75.70 crore against a loss in the previous year.
Key Highlights
Consolidated revenue from operations stood at ₹719.80 crore, up 5.5% YoY from ₹682.34 crore.
Reported a consolidated net loss of ₹12.97 crore for Q3 FY26 versus a profit of ₹4.63 crore in Q3 FY25.
Operating EBITDA margin contracted significantly to 15.71% from 20.61% in the same quarter last year.
Employee benefit expenses increased to ₹355.88 crore, representing nearly 49% of total income.
9-month FY26 consolidated net profit reached ₹75.70 crore, recovering from a loss of ₹39.85 crore in 9M FY25.
💼 Action for Investors
Investors should exercise caution as the company has returned to a quarterly loss despite revenue growth, indicating pressure on margins and high fixed costs. Close monitoring of cost-rationalization measures and debt-equity levels (currently at 0.43) is advised.
DCAL Allots ₹50 Crore Senior Secured NCDs via Private Placement
Dishman Carbogen Amcis Limited (DCAL) has successfully allotted 5,000 Senior, Secured, Rated, Listed NCDs. The total capital raised through this private placement is ₹50 crore, with each debenture priced at ₹1,00,000. These debentures have a three-year tenure, maturing on January 20, 2029. This fundraise is part of the company's financial management strategy to secure long-term capital for its operations.
Key Highlights
Allotment of 5,000 Senior, Secured, Rated, and Listed NCDs
Total aggregate amount raised is ₹50 crore via private placement
Face value of each debenture is ₹1,00,000 issued at par
Maturity date is set for January 20, 2029, representing a 3-year term
💼 Action for Investors
Investors should monitor the company's debt-to-equity ratio and interest coverage to ensure the new debt remains manageable. No immediate action is required as this is a relatively small-scale fundraise for the company.
DCAL Board Approves Rs 50 Crore NCD Issuance at 10% Coupon Rate
Dishman Carbogen Amcis Limited (DCAL) has approved the issuance of Senior, Secured, Rated NCDs aggregating up to Rs 50 crores on a private placement basis. The debt instruments carry a coupon rate of 10.00% per annum, with interest and principal payable on a quarterly basis. The tenure is set for 36 months, featuring a quarterly amortization schedule of 12 equal tranches. The issue is backed by a 1.1x security cover including company assets, promoter-owned land, and personal guarantees.
Key Highlights
Issuance of up to 5,000 NCDs with a face value of Rs 1,00,000 each, totaling Rs 50 crores
Fixed coupon rate of 10.00% per annum with quarterly interest and principal payments
Tenure of 36 months with principal to be redeemed in 12 equal quarterly tranches
Security cover of 1.1x provided through company assets, promoter land, and personal guarantees
Proposed listing on the Wholesale Debt Market Segment of BSE Limited
💼 Action for Investors
Investors should monitor the company's cash flow capacity to service the quarterly principal and interest repayments. While the fundraise amount is relatively small, the 10% interest rate reflects the current cost of debt for the company.
DCAL Board Approves Rs. 50 Crore Fundraise via Secured NCDs at 10% Coupon
Dishman Carbogen Amcis Limited (DCAL) has approved the issuance of Senior, Secured, Rated, Listed Non-Convertible Debentures (NCDs) totaling Rs. 50 crores. These NCDs carry a coupon rate of 10.00% per annum, with both interest and principal to be paid on a quarterly basis. The debt has a tenure of 36 months and is structured with a quarterly amortization schedule of 12 equal tranches. The issue is backed by a 1.1x security cover, including charges on specific properties and personal/corporate guarantees.
Key Highlights
Issuance of 5,000 NCDs with a face value of Rs. 1,00,000 each, aggregating to Rs. 50 crores.
Fixed coupon rate of 10.00% per annum with a quarterly payment frequency.
Tenure of 36 months with principal repayment in 12 equal quarterly amortizing tranches.
Secured by 1.1x cover on specific immovable properties in Ahmedabad and the Naroda Plant.
Includes personal guarantee from Promoter Mr. Arpit Vyas and corporate guarantee from Dishman Infrastructure Ltd.
💼 Action for Investors
Investors should monitor the company's quarterly cash flows to ensure they can comfortably service the high-frequency amortization and 10% interest payments. While the fundraise amount is relatively small, the structured repayment schedule requires disciplined liquidity management.